FDA rejects first-in-class osteoporosis drug

Nature Reviews Drug Discovery 16, 593 (2017). doi:10.1038/nrd.2017.176 Author: Asher Mullard The FDA rejected Amgen's and UCB's romosozumab, an anti-sclerostin monoclonal antibody that the firms are developing for the treatment of osteoporosis. The rejection followed on the heels of a cardiovascular safety signal that the companies reported in May. Amgen and UCB are now working
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: News and Analysis Source Type: research